Cross-priming	O
of	O
CTL	O
responses	O
in	O
vivo	O
does	O
not	O
require	O
antigenic	O
peptides	O
in	O
the	O
endoplasmic	O
reticulum	O
of	O
immunizing	B-cell_type
cells	I-cell_type
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
cross-priming	O
of	O
CTL	O
responses	O
in	O
vivo	O
involves	O
the	O
transfer	O
to	O
host	O
APCs	B-cell_type
of	O
heat	B-protein
shock	I-protein
protein	I-protein
glycoprotein	I-protein
96	I-protein
-chaperoned	O
antigenic	O
peptides	O
released	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
of	O
dying	B-cell_type
or	I-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
tested	O
this	O
possibility	O
directly	O
using	O
TAP-deficient	B-cell_line
cell	I-cell_line
lines	I-cell_line
lacking	O
antigenic	O
ER	O
peptides	O
derived	O
from	O
two	O
model	O
Ags	B-protein
,	O
the	O
human	B-protein
adenovirus	I-protein
type	I-protein
5	I-protein
early	I-protein
regions	I-protein
E1A	I-protein
and	I-protein
E1B	I-protein
.	O

Although	O
both	O
proteins	O
were	O
well	O
expressed	O
,	O
the	O
cells	O
were	O
not	O
recognized	O
by	O
E1A-	B-cell_type
or	I-cell_type
E1B-specific	I-cell_type
CTLs	I-cell_type
unless	O
the	O
relevant	O
epitope	O
was	O
either	O
provided	O
exogenously	O
as	O
a	O
synthetic	O
peptide	O
or	O
targeted	O
to	O
the	O
ER	O
in	O
a	O
TAP-independent	O
fashion	O
.	O

Despite	O
the	O
absence	O
of	O
these	O
ER	O
peptides	O
,	O
the	O
TAP1-/-	B-cell_type
cells	I-cell_type
were	O
able	O
to	O
efficiently	O
cross-prime	B-cell_type
E1A-	I-cell_type
and	I-cell_type
E1B-specific	I-cell_type
CTLs	I-cell_type
following	O
immunization	O
of	O
syngeneic	O
mice	O
.	O

These	O
results	O
indicate	O
that	O
,	O
although	O
purified	O
peptide/glycoprotein	B-protein
96	I-protein
complexes	I-protein
are	O
potent	O
immunogens	O
,	O
the	O
mechanism	O
of	O
CTL	O
cross-priming	O
in	O
vivo	O
does	O
not	O
depend	O
upon	O
antigenic	O
peptides	O
in	O
the	O
ER	O
of	O
immunizing	B-cell_type
cells	I-cell_type
.	O

K	NULL
Boldly	NULL
GolnVivo	NULL
``	NULL
``	NULL
BioLegend®	NULL
#	NULL
s	NULL
me	NULL
Journal	NULL
of	NULL
Cutting	NULL
Edge	NULL
:	NULL
Cross-Priming	NULL
of	NULL
CTL	NULL
'D	NULL
Immunolo	NULL
gy	NULL
Responses	NULL
In	NULL
Vivo	NULL
Does	NULL
Not	NULL
Require	NULL
Antigenic	NULL
Peptides	NULL
in	NULL
the	NULL
Endoplasmic	NULL
Reticulum	NULL
of	NULL
Immunizing	NULL
Cells	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Stephen	NULL
P.	NULL
Schoenberger	NULL
,	NULL
Ellen	NULL
I.	NULL
H.	NULL
van	NULL
der	NULL
Voort	NULL
,	NULL
G.	NULL
Menno	NULL
Krietemejjer	NULL
,	NULL
Rienk	NULL
Offringa	NULL
,	NULL
Cornelis	NULL
J.	NULL
M.	NULL
Melief	NULL
and	NULL
Rene	NULL
E.	NULL
M.	NULL
Toes	NULL
J	NULL
Immunol	NULL
1998	NULL
;	NULL
161:3808-3812	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/161/8/3808	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
29	NULL
articles	NULL
,	NULL
17	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/161/8/3808	NULL
.	NULL

full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
(	NULL
CTIDG	NULL
€	NULL
=\	NULL
e	NULL
a	NULL
)	NULL
Cutting	NULL
Edge	NULL
:	NULL
Cross-Priming	NULL
of	NULL
CTL	NULL
Responses	NULL
In	NULL
Vivo	NULL
Does	NULL
Not	NULL
Require	NULL
Antigenic	NULL
Peptides	NULL
in	NULL
the	NULL
Endoplasmic	NULL
Reticulum	NULL
of	NULL
Immunizing	NULL
Cells	NULL
!	NULL

Stephen	NULL
P.	NULL
Schoenberger	NULL
,	NULL
``	NULL
Ellen	NULL
I.	NULL
H.	NULL
van	NULL
der	NULL
Voort	NULL
,	NULL
G.	NULL
Menno	NULL
Krietemejjer	NULL
,	NULL
Rienk	NULL
Offringa	NULL
,	NULL
Cornelis	NULL
J.	NULL
M.	NULL
Melief	NULL
,	NULL
and	NULL
Rene	NULL
E.	NULL
M.	NULL
Toes	NULL
It	NULL
has	NULL
been	NULL
proposed	NULL
that	NULL
the	NULL
cross-priming	NULL
of	NULL
CTL	NULL
responses	NULL
in	NULL
vivo	NULL
involves	NULL
the	NULL
transfer	NULL
to	NULL
host	NULL
APCs	NULL
of	NULL
heat	NULL
shock	NULL
protein	NULL
glycoprotein	NULL
96-chaperoned	NULL
antigenic	NULL
peptides	NULL
released	NULL
from	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
(	NULL
ER	NULL
)	NULL
of	NULL
dying	NULL
or	NULL
infected	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
tested	NULL
this	NULL
possibility	NULL
directly	NULL
using	NULL
TAP-deficient	NULL
cell	NULL
lines	NULL
lacking	NULL
antigenic	NULL
ER	NULL
peptides	NULL
derived	NULL
from	NULL
two	NULL
model	NULL
Ags	NULL
,	NULL
the	NULL
human	NULL
adenovirus	NULL
type	NULL
5	NULL
early	NULL
regions	NULL
E1A	NULL
and	NULL
E1B	NULL
.	NULL

Although	NULL
both	NULL
proteins	NULL
were	NULL
well	NULL
expressed	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
not	NULL
recognized	NULL
by	NULL
E1A-	NULL
or	NULL
E1B-specific	NULL
CTLs	NULL
unless	NULL
the	NULL
relevant	NULL
epitope	NULL
was	NULL
either	NULL
provided	NULL
exogenously	NULL
as	NULL
a	NULL
synthetic	NULL
peptide	NULL
or	NULL
targeted	NULL
to	NULL
the	NULL
ER	NULL
in	NULL
a	NULL
TAP-independent	NULL
fashion	NULL
.	NULL

Despite	NULL
the	NULL
absence	NULL
of	NULL
these	NULL
ER	NULL
peptides	NULL
,	NULL
the	NULL
TAP1~'~	NULL
cells	NULL
were	NULL
able	NULL
to	NULL
efficiently	NULL
cross-prime	NULL
E1A-	NULL
and	NULL
E1B-specific	NULL
CTLs	NULL
following	NULL
immunization	NULL
of	NULL
syngeneic	NULL
mice	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
,	NULL
although	NULL
purified	NULL
peptide/glycoprotein	NULL
96	NULL
complexes	NULL
are	NULL
potent	NULL
immunogens	NULL
,	NULL
the	NULL
mechanism	NULL
of	NULL
CTL	NULL
cross-priming	NULL
in	NULL
vivo	NULL
does	NULL
not	NULL
depend	NULL
upon	NULL
antigenic	NULL
peptides	NULL
in	NULL
the	NULL
ER	NULL
of	NULL
immunizing	NULL
cells	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1998	NULL
,	NULL
161	NULL
:	NULL
3808-3812.	NULL
ross-priming	NULL
refers	NULL
to	NULL
the	NULL
uptake	NULL
and	NULL
MHC	NULL
class	NULL
I-restricted	NULL
presentation	NULL
of	NULL
exogenous	NULL
cell-associated	NULL
Ag	NULL
by	NULL
professional	NULL
host	NULL
APCs	NULL
that	NULL
results	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
CTLs	NULL
.	NULL

Originally	NULL
invoked	NULL
as	NULL
a	NULL
mechanism	NULL
to	NULL
explain	NULL
the	NULL
ability	NULL
of	NULL
MHC-mismatched	NULL
grafts	NULL
to	NULL
induce	NULL
host	NULL
MHC-restricted	NULL
CTLs	NULL
,	NULL
the	NULL
indirect	NULL
presentation	NULL
pathway	NULL
is	NULL
believed	NULL
to	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
immune	NULL
surveillance	NULL
and	NULL
regulation	NULL
by	NULL
facilitating	NULL
the	NULL
transfer	NULL
of	NULL
Ags	NULL
synthesized	NULL
in	NULL
nonhemopoetic	NULL
tissues	NULL
to	NULL
lymphoid	NULL
organs	NULL
for	NULL
presentation	NULL
to	NULL
naive	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Recent	NULL
evidence	NULL
now	NULL
indicates	NULL
Department	NULL
of	NULL
Immunohematology	NULL
and	NULL
Blood	NULL
Bank	NULL
,	NULL
University	NULL
Hospital	NULL
Leiden	NULL
,	NULL
Leiden	NULL
,	NULL
The	NULL
Netherlands	NULL
Received	NULL
for	NULL
publication	NULL
June	NULL
25	NULL
,	NULL
1998	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
August	NULL
10	NULL
,	NULL
1998	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
work	NULL
was	NULL
funded	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Dutch	NULL
Cancer	NULL
Society	NULL
and	NULL
the	NULL
European	NULL
Community	NULL
.	NULL

The	NULL
research	NULL
of	NULL
R.E.M.T	NULL
.	NULL

has	NULL
been	NULL
made	NULL
possible	NULL
by	NULL
a	NULL
fellowship	NULL
of	NULL
the	NULL
Royal	NULL
Netherlands	NULL
Academy	NULL
of	NULL
Arts	NULL
and	NULL
Sciences	NULL
.	NULL

2	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Stephen	NULL
P.	NULL
Schoenberger	NULL
,	NULL
Division	NULL
of	NULL
Immune	NULL
Regulation	NULL
,	NULL
La	NULL
Jolla	NULL
Institute	NULL
for	NULL
Allergy	NULL
and	NULL
Immunology	NULL
,	NULL
10355	NULL
Science	NULL
Center	NULL
Drive	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
92121	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
sps	NULL
@	NULL
liai.org	NULL
Copyright	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
that	NULL
,	NULL
under	NULL
certain	NULL
circumstances	NULL
,	NULL
cross-presentation	NULL
of	NULL
self	NULL
Ags	NULL
from	NULL
healthy	NULL
tissues	NULL
can	NULL
also	NULL
lead	NULL
to	NULL
deletion	NULL
rather	NULL
than	NULL
activation	NULL
of	NULL
T	NULL
cell	NULL
responses	NULL
in	NULL
a	NULL
process	NULL
termed	NULL
``	NULL
cross-tolerance	NULL
``	NULL
(	NULL
re-viewed	NULL
in	NULL
ref	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Although	NULL
many	NULL
details	NULL
of	NULL
the	NULL
cross-priming	NULL
pathway	NULL
have	NULL
been	NULL
revealed	NULL
,	NULL
a	NULL
central	NULL
question	NULL
remains	NULL
the	NULL
mechanism	NULL
through	NULL
which	NULL
host	NULL
APCs	NULL
are	NULL
able	NULL
to	NULL
introduce	NULL
peptides	NULL
derived	NULL
from	NULL
exogenous	NULL
protein	NULL
Ags	NULL
into	NULL
their	NULL
own	NULL
class	NULL
I	NULL
presentation	NULL
pathway	NULL
(	NULL
4	NULL
)	NULL
.	NULL

A	NULL
potential	NULL
solution	NULL
has	NULL
emerged	NULL
in	NULL
the	NULL
identification	NULL
of	NULL
a	NULL
group	NULL
of	NULL
heat	NULL
shock	NULL
proteins	NULL
(	NULL
hsps	NULL
)	NULL
that	NULL
are	NULL
able	NULL
to	NULL
confer	NULL
tumor-specific	NULL
immunity	NULL
through	NULL
their	NULL
association	NULL
with	NULL
antigenic	NULL
peptides	NULL
derived	NULL
from	NULL
intracellular	NULL
proteins	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

The	NULL
best-characterized	NULL
and	NULL
most	NULL
immunogenic	NULL
of	NULL
these	NULL
hsps	NULL
,	NULL
glycoprotein	NULL
(	NULL
gp	NULL
)	NULL
96	NULL
,	NULL
is	NULL
an	NULL
abundant	NULL
component	NULL
of	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
(	NULL
ER	NULL
)	NULL
(	NULL
8	NULL
)	NULL
.	NULL

In	NULL
the	NULL
ER	NULL
,	NULL
gp96	NULL
binds	NULL
to	NULL
TAP-transported	NULL
peptides	NULL
generated	NULL
by	NULL
cytosolic	NULL
Ag	NULL
processing	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

In	NULL
this	NULL
capacity	NULL
,	NULL
gp96	NULL
can	NULL
associate	NULL
with	NULL
a	NULL
repertoire	NULL
of	NULL
antigenic	NULL
peptides	NULL
identical	NULL
with	NULL
the	NULL
repertoire	NULL
of	NULL
proteins	NULL
expressed	NULL
inside	NULL
the	NULL
same	NULL
cell	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
experimental	NULL
evidence	NULL
support	NULL
a	NULL
direct	NULL
role	NULL
for	NULL
gp96	NULL
in	NULL
the	NULL
cross-priming	NULL
of	NULL
CTLs	NULL
in	NULL
vivo	NULL
.	NULL

First	NULL
,	NULL
immunization	NULL
with	NULL
gp96	NULL
purified	NULL
from	NULL
allogeneic	NULL
tumor	NULL
or	NULL
virus-infected	NULL
cells	NULL
can	NULL
elicit	NULL
host	NULL
MHC-restricted	NULL
CTLs	NULL
directed	NULL
against	NULL
the	NULL
Ags	NULL
expressed	NULL
by	NULL
the	NULL
cells	NULL
from	NULL
which	NULL
it	NULL
was	NULL
isolated	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

This	NULL
specific	NULL
immunogenicity	NULL
is	NULL
lost	NULL
when	NULL
gp96	NULL
is	NULL
stripped	NULL
of	NULL
bound	NULL
peptides	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
gp96	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
endogenously	NULL
associate	NULL
with	NULL
the	NULL
same	NULL
immunodominant	NULL
vesicular	NULL
stomatitis	NULL
virus	NULL
peptide	NULL
in	NULL
vesicular	NULL
stomatitis	NULL
virus-infected	NULL
cells	NULL
of	NULL
different	NULL
MHC	NULL
types	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
a	NULL
subset	NULL
of	NULL
macrophages	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
purified	NULL
gp96	NULL
in	NULL
vitro	NULL
and	NULL
direct	NULL
the	NULL
bound	NULL
peptides	NULL
into	NULL
its	NULL
own	NULL
class	NULL
I	NULL
processing	NULL
and	NULL
presentation	NULL
pathway	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
observations	NULL
,	NULL
Suto	NULL
et	NULL
al	NULL
.	NULL

proposed	NULL
a	NULL
mechanism	NULL
of	NULL
cross-priming	NULL
in	NULL
which	NULL
the	NULL
gp96-chaperoned	NULL
peptides	NULL
released	NULL
by	NULL
dying	NULL
or	NULL
infected	NULL
cells	NULL
bind	NULL
to	NULL
unknown	NULL
receptors	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
macrophages	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
complexes	NULL
are	NULL
then	NULL
internalized	NULL
,	NULL
and	NULL
the	NULL
bound	NULL
peptides	NULL
are	NULL
routed	NULL
to	NULL
the	NULL
class	NULL
I	NULL
processing	NULL
machinery	NULL
of	NULL
the	NULL
macrophages	NULL
for	NULL
subsequent	NULL
presentation	NULL
to	NULL
CTLs	NULL
.	NULL

This	NULL
model	NULL
of	NULL
cross-priming	NULL
is	NULL
attractive	NULL
because	NULL
it	NULL
not	NULL
only	NULL
preserves	NULL
the	NULL
logic	NULL
of	NULL
what	NULL
type	NULL
of	NULL
Ags	NULL
should	NULL
be	NULL
directed	NULL
for	NULL
presentation	NULL
via	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
but	NULL
also	NULL
identifies	NULL
a	NULL
host	NULL
APC	NULL
subset	NULL
capable	NULL
of	NULL
3	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
hsp	NULL
,	NULL
heat	NULL
shock	NULL
protein	NULL
;	NULL
gp	NULL
,	NULL
glycoprotein	NULL
;	NULL
ER	NULL
,	NULL
endoplasmic	NULL
reticulum	NULL
;	NULL
MEC	NULL
,	NULL
murine	NULL
embryo	NULL
cell	NULL
;	NULL
E1	NULL
,	NULL
early	NULL
region	NULL
1	NULL
;	NULL
5E1	NULL
,	NULL
human	NULL
adenovirus	NULL
type	NULL
5	NULL
E1	NULL
;	NULL
wt	NULL
,	NULL
wild-type	NULL
.	NULL

0022-1767/98/	NULL
$	NULL
02.00	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
transferring	NULL
the	NULL
exogenous	NULL
gp96-peptide	NULL
complexes	NULL
to	NULL
its	NULL
own	NULL
en-dogenous	NULL
MHC	NULL
class	NULL
I	NULL
presentation	NULL
pathway	NULL
.	NULL

Despite	NULL
the	NULL
numerous	NULL
studies	NULL
showing	NULL
that	NULL
gp96	NULL
purified	NULL
from	NULL
cells	NULL
can	NULL
prime	NULL
CTL	NULL
responses	NULL
in	NULL
vivo	NULL
and	NULL
the	NULL
implicit	NULL
logic	NULL
of	NULL
the	NULL
proposed	NULL
gp96-dependent	NULL
cross-priming	NULL
pathway	NULL
,	NULL
the	NULL
relevance	NULL
of	NULL
gp96	NULL
to	NULL
``	NULL
classical	NULL
``	NULL
cross-priming	NULL
involving	NULL
cell-associated	NULL
Ags	NULL
has	NULL
not	NULL
been	NULL
directly	NULL
tested	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
have	NULL
used	NULL
immunization	NULL
with	NULL
TAP-deficient	NULL
cells	NULL
lacking	NULL
defined	NULL
ER	NULL
peptides	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
mechanism	NULL
underlying	NULL
in	NULL
vivo	NULL
cross-priming	NULL
of	NULL
CTL	NULL
responses	NULL
requires	NULL
antigenic	NULL
peptides	NULL
in	NULL
the	NULL
ER	NULL
of	NULL
immunizing	NULL
cells	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Mice	NULL
and	NULL
cell	NULL
lines	NULL
TAP1	NULL
~*~	NULL
and	NULL
wild-type	NULL
(	NULL
wt	NULL
)	NULL
TAP*'*	NULL
C57BL/6	NULL
mice	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
A.	NULL
Berns	NULL
of	NULL
the	NULL
Netherlands	NULL
Cancer	NULL
Institute	NULL
.	NULL

Murine	NULL
embryo	NULL
cells	NULL
(	NULL
MECs	NULL
)	NULL
expressing	NULL
human	NULL
adenovirus	NULL
type	NULL
5	NULL
early	NULL
region	NULL
1	NULL
(	NULL
5E1	NULL
)	NULL
were	NULL
generated	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
15	NULL
)	NULL
.	NULL

MECs	NULL
expressing	NULL
the	NULL
SigE1A	NULL
;	NULL
;	NULL
4	NULL
,	NULL
343	NULL
or	NULL
pSigE1B19	NULL
;	NULL
20p	NULL
minigenes	NULL
were	NULL
transfected	NULL
by	NULL
electro-poration	NULL
(	NULL
Gene	NULL
Pulser	NULL
,	NULL
Bio-Rad	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
SigB1Apy	NULL
,	NULL
p43	NULL
plasmid	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
SigE1B19	NULL
;	NULL
20	NULL
,	NULL
plasmid	NULL
wasconstructedbyligationoftheduplexoligonucleotide5'-GTAAATATCAG	NULL
GAATTGTTGCTACATTTATAGTCCTITTAACAACGA-3	NULL
'	NULL
,	NULL
encoding	NULL
the	NULL
E1B	NULL
CTL	NULL
epitope	NULL
,	NULL
into	NULL
NofW/Swal-digested	NULL
pSPCV-DR2	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Immunochemical	NULL
detection	NULL
of	NULL
EIA	NULL
and	NULL
EIB	NULL
proteins	NULL
Expression	NULL
of	NULL
E1A	NULL
and	NULL
E1B	NULL
proteins	NULL
was	NULL
detected	NULL
on	NULL
cells	NULL
fixed	NULL
onto	NULL
glass	NULL
microscope	NULL
slides	NULL
using	NULL
Abs	NULL
specific	NULL
for	NULL
ElA	NULL
(	NULL
mAb	NULL
M73A11	NULL
)	NULL
or	NULL
E1B	NULL
proteins	NULL
(	NULL
mAb	NULL
A1C6	NULL
)	NULL
followed	NULL
by	NULL
a	NULL
horseradish	NULL
peroxidase-labeled	NULL
second	NULL
Ab	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Micrographs	NULL
were	NULL
taken	NULL
on	NULL
a	NULL
Zeiss	NULL
Axiophot	NULL
light	NULL
microscope	NULL
(	NULL
Carl	NULL
Zeiss	NULL
,	NULL
Jena	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Images	NULL
were	NULL
scanned	NULL
and	NULL
prepared	NULL
using	NULL
Adobe	NULL
Photoshop	NULL
(	NULL
Adobe	NULL
Systems	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

CTL	NULL
recognition	NULL
assays	NULL
Experimental	NULL
procedures	NULL
to	NULL
measure	NULL
cell-mediated	NULL
lysis	NULL
were	NULL
performed	NULL
using	NULL
the	NULL
chromium	NULL
release	NULL
assay	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
19	NULL
)	NULL
.	NULL

For	NULL
the	NULL
TNE-secretion	NULL
assay	NULL
,	NULL
2	NULL
X	NULL
10°	NULL
target	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
round-bottom	NULL
96-well	NULL
plates	NULL
with	NULL
2.5	NULL
X	NULL
10°	NULL
CTLs	NULL
in	NULL
150	NULL
pl	NULL
of	NULL
medium	NULL
containing	NULL
10	NULL
Cetus	NULL
units	NULL
of	NULL
rIL-2	NULL
(	NULL
Cetus	NULL
,	NULL
Emeryville	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
collected	NULL
after	NULL
24	NULL
h	NULL
,	NULL
and	NULL
its	NULL
TNF	NULL
content	NULL
was	NULL
determined	NULL
by	NULL
measuring	NULL
its	NULL
cytotoxicity	NULL
on	NULL
WEHI-164	NULL
clone	NULL
13	NULL
cells	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Immunizations	NULL
and	NULL
bulk	NULL
CTL	NULL
cultures	NULL
Groups	NULL
of	NULL
mice	NULL
were	NULL
immunized	NULL
once	NULL
with	NULL
1	NULL
X	NULL
10	NULL
``	NULL
irradiated	NULL
(	NULL
25	NULL
Gy	NULL
)	NULL
cells	NULL
in	NULL
0.2	NULL
ml	NULL
PBS	NULL
.	NULL

After	NULL
2	NULL
wk	NULL
,	NULL
splenocytes	NULL
were	NULL
harvested	NULL
and	NULL
cocultivated	NULL
at	NULL
5	NULL
X	NULL
10°	NULL
cells/well	NULL
with	NULL
5E1-transformed	NULL
stimulator	NULL
cells	NULL
at	NULL
a	NULL
ratio	NULL
of	NULL
10:1	NULL
in	NULL
24-well	NULL
plates	NULL
.	NULL

Following	NULL
a	NULL
6-day	NULL
coculture	NULL
,	NULL
viable	NULL
lymphocytes	NULL
were	NULL
collected	NULL
and	NULL
tested	NULL
for	NULL
cytotoxicity	NULL
on	NULL
europium-labeled	NULL
target	NULL
cells	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Results	NULL
In	NULL
vitro	NULL
transformation	NULL
of	NULL
TAPI	NULL
``	NULL
~	NULL
cells	NULL
To	NULL
obtain	NULL
cell	NULL
lines	NULL
lacking	NULL
ER	NULL
expression	NULL
of	NULL
antigenic	NULL
peptides	NULL
derived	NULL
from	NULL
nuclear	NULL
and	NULL
cytosolic	NULL
proteins	NULL
,	NULL
MEC	NULL
's	NULL
from	NULL
TAP1	NULL
'~	NULL
or	NULL
wt	NULL
(	NULL
TAP	NULL
*'*	NULL
)	NULL
mice	NULL
were	NULL
transfected	NULL
with	NULL
5E1	NULL
encoding	NULL
the	NULL
E1A	NULL
and	NULL
E1B	NULL
oncogenes	NULL
.	NULL

This	NULL
yielded	NULL
TAP1~'~	NULL
5E1-MECs	NULL
and	NULL
TAP*'*	NULL
5E1-MECs	NULL
,	NULL
respectively	NULL
.	NULL

C57BL/6	NULL
(	NULL
H-2	NULL
``	NULL
)	NULL
MECs	NULL
were	NULL
chosen	NULL
for	NULL
transformation	NULL
with	NULL
5E1	NULL
because	NULL
they	NULL
allow	NULL
the	NULL
use	NULL
of	NULL
H-2D-restricted	NULL
E1	NULL
A-	NULL
and	NULL
E1B-specific	NULL
CTL	NULL
clones	NULL
to	NULL
test	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
antigenic	NULL
peptides	NULL
derived	NULL
from	NULL
these	NULL
two	NULL
independent	NULL
Ags	NULL
(	NULL
15	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Both	NULL
TAP_'~	NULL
and	NULL
TAP*'*~	NULL
MECs	NULL
were	NULL
found	NULL
to	NULL
express	NULL
low	NULL
but	NULL
detectable	NULL
levels	NULL
of	NULL
surface	NULL
H-2D	NULL
``	NULL
molecules	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Exposure	NULL
to	NULL
IFN-y	NULL
up-regulated	NULL
the	NULL
surface	NULL
D	NULL
``	NULL
expression	NULL
on	NULL
3809	NULL
Relative	NULL
cell	NULL
number	NULL
Log	NULL
Mean	NULL
Fluorescence	NULL
FIGURE	NULL
1	NULL
.	NULL

-	NULL
Surface	NULL
H-2D	NULL
``	NULL
levels	NULL
on	NULL
wt	NULL
and	NULL
TAP1~~	NULL
MECs	NULL
.	NULL

The	NULL
surface	NULL
levels	NULL
of	NULL
H-2D	NULL
``	NULL
molecules	NULL
on	NULL
wt	NULL
TAP1	NULL
**	NULL
MECs	NULL
(	NULL
4	NULL
)	NULL
,	NULL
TAP1	NULL
***	NULL
5E1-MECs	NULL
(	NULL
B	NULL
)	NULL
,	NULL
TAP1	NULL
~~	NULL
MECs	NULL
(	NULL
C	NULL
)	NULL
,	NULL
or	NULL
TAP1	NULL
~~	NULL
5E1-MECs	NULL
(	NULL
D	NULL
)	NULL
are	NULL
depicted	NULL
in	NULL
a	NULL
cytofluorometric	NULL
analysis	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
either	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
thick	NULL
line	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
thin	NULL
line	NULL
)	NULL
of	NULL
10	NULL
U/ml	NULL
IFN-y	NULL
for	NULL
48	NULL
h	NULL
before	NULL
staining	NULL
with	NULL
the	NULL
H-2D	NULL
``	NULL
-specific	NULL
mAb	NULL
H1413110	NULL
followed	NULL
by	NULL
secondary	NULL
staining	NULL
with	NULL
an	NULL
FITC-conjugated	NULL
anti-mouse	NULL
Ab	NULL
.	NULL

The	NULL
dotted	NULL
line	NULL
indicates	NULL
the	NULL
background	NULL
fluorescence	NULL
of	NULL
cells	NULL
stained	NULL
with	NULL
secondary	NULL
Ab	NULL
alone	NULL
.	NULL

both	NULL
TAP	NULL
**	NULL
MECs	NULL
and	NULL
TAP	NULL
*'*	NULL
5E1-MECs	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
surface	NULL
D	NULL
``	NULL
expression	NULL
on	NULL
the	NULL
TAP1~'~	NULL
MECs	NULL
and	NULL
TAP_~'~	NULL
5E1-MECs	NULL
was	NULL
not	NULL
substantially	NULL
increased	NULL
following	NULL
exposure	NULL
to	NULL
IFN-y	NULL
,	NULL
reflecting	NULL
the	NULL
absence	NULL
of	NULL
TAP-translocated	NULL
peptides	NULL
in	NULL
the	NULL
ER	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

Although	NULL
both	NULL
the	NULL
E1A	NULL
and	NULL
E1B	NULL
proteins	NULL
are	NULL
abundantly	NULL
expressed	NULL
in	NULL
both	NULL
the	NULL
TAP	NULL
**	NULL
5E1-MEC	NULL
's	NULL
and	NULL
TAP1	NULL
'~	NULL
5E1-MECs	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
only	NULL
the	NULL
wt	NULL
TAP	NULL
*'*	NULL
5E1-MEC	NULL
's	NULL
are	NULL
recognized	NULL
by	NULL
E1A-and	NULL
E1B-specific	NULL
CTL	NULL
clones	NULL
in	NULL
a	NULL
cytotoxicity	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
A	NULL
and	NULL
A	NULL
B	NULL
*	NULL
‘	NULL
a	NULL
€	NULL
w	NULL
``	NULL
._	NULL
‘	NULL
A	NULL
%	NULL
,	NULL
®	NULL
%	NULL
S	NULL
p	NULL
~®	NULL
*	NULL
,	NULL
C	NULL
wos	NULL
%	NULL
aeg	NULL
s	NULL
Cait	NULL
oP	NULL
``	NULL
ye	NULL
f	NULL
*	NULL
&	NULL
2	NULL
#	NULL
«	NULL
#	NULL
$	NULL
``	NULL
SP	NULL
FIGURE	NULL
2	NULL
.	NULL

Expression	NULL
of	NULL
ElA	NULL
and	NULL
E1B	NULL
proteins	NULL
by	NULL
TAP1	NULL
'~	NULL
5E1-MECs	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
ElA	NULL
(	NULL
A	NULL
and	NULL
C	NULL
)	NULL
and	NULL
E1B	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
proteins	NULL
by	NULL
TAP1	NULL
~*~	NULL
MECs	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
5E1-transformed	NULL
~~	NULL
MECs	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
was	NULL
detected	NULL
by	NULL
immunochemistry	NULL
with	NULL
specific	NULL
Abs	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Magnification	NULL
=	NULL
X400	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
3810	NULL
E1A	NULL
CTL	NULL
E1B	NULL
CTL	NULL
A	NULL
B	NULL
100	NULL
100	NULL
a	NULL
P4	NULL
Fa	NULL
%	NULL
7s	NULL
3	NULL
75	NULL
2	NULL
5	NULL
'	NULL
o	NULL
©	NULL
50	NULL
§	NULL
so	NULL
8	NULL
a	NULL
a*	NULL
®	NULL
oop	NULL
25	NULL
o/O—H	NULL
i	NULL
*	NULL
t	NULL
s	NULL
2s	NULL
20	NULL
10°	NULL
5	NULL
25	NULL
°	NULL
``	NULL
er	NULL
Em	NULL
D	NULL
C	NULL
100	NULL
100	NULL
5	NULL
£	NULL
&	NULL
&	NULL
$	NULL
75	NULL
8	NULL
7	NULL
©	NULL
©	NULL
0	NULL
O	NULL
©	NULL
50	NULL
©	NULL
50	NULL
§	NULL
3	NULL
yo	NULL
25	NULL
a	NULL
25	NULL
o	NULL
o	NULL
=	NULL
o	NULL
o	NULL
o	NULL
o	NULL
§	NULL
o	NULL
o	NULL
0	NULL
g	NULL
§	NULL
§	NULL
8	NULL
§	NULL
4	NULL
g	NULL
Target	NULL
§	NULL
$	NULL
E	NULL
3	NULL
g	NULL
Target	NULL
-o	NULL
2	NULL
o	NULL
2s	NULL
Lom	NULL
m	NULL
mos	NULL
8	NULL
5	NULL
5	NULL
§	NULL
°	NULL
k	NULL
E	NULL
k	NULL
E	NULL
&	NULL
d	NULL
dod	NULL
.	NULL

&	NULL
og	NULL
&	NULL
¢	NULL
&	NULL
@	NULL
<	NULL
@	NULL
<	NULL
f	NULL
f	NULL
R	NULL
COCO	NULL
m	NULL
CO	NULL
Os	NULL
a	NULL
5	NULL
©	NULL
e	NULL
a	NULL
g	NULL
m	NULL
®	NULL
FIGURE	NULL
3	NULL
.	NULL

-	NULL
Recognition	NULL
of	NULL
TAP1	NULL
**	NULL
and	NULL
TAP1~~	NULL
5E1-MECs	NULL
by	NULL
specific	NULL
CTLs	NULL
.	NULL

The	NULL
recognition	NULL
of	NULL
IFN-y-treated	NULL
(	NULL
48-h	NULL
)	NULL
TAP1	NULL
***	NULL
5E1-MECs	NULL
and	NULL
TAP1	NULL
~~	NULL
5E1-MECs	NULL
by	NULL
E1	NULL
A-specific	NULL
(	NULL
A	NULL
and	NULL
C	NULL
)	NULL
or	NULL
E1B-specific	NULL
CTLs	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
was	NULL
tested	NULL
in	NULL
chromium	NULL
release	NULL
assays	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
TNF-se-cretion	NULL
assays	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Target	NULL
cells	NULL
were	NULL
TAP1**	NULL
5E1-MECs	NULL
(	NULL
C	NULL
)	NULL
)	NULL
,	NULL
TAP1~~	NULL
5E1-MECs	NULL
(	NULL
O	NULL
)	NULL
,	NULL
or	NULL
TAP1~'~	NULL
5EL-MECs	NULL
pulsed	NULL
with	NULL
either	NULL
SEA	NULL
,	NULL
,	NULL
,	NULL
,	NULL
;	NULL
peptide	NULL
(	NULL
@	NULL
)	NULL
or	NULL
E1B	NULL
;	NULL
9	NULL
;	NULL
20	NULL
,	NULL
peptide	NULL
(	NULL
M	NULL
)	NULL
.	NULL

SigE1	NULL
A/TAP-5E1-MECs	NULL
and	NULL
SigE1B/TAP-5E1-MECs	NULL
are	NULL
transfectants	NULL
of	NULL
TAP1	NULL
~~	NULL
5E1-MECs	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Peptide-pulsed	NULL
targets	NULL
were	NULL
incubated	NULL
with	NULL
either	NULL
El1A	NULL
;	NULL
34	NULL
243	NULL
Of	NULL
E1B19	NULL
;	NULL
20	NULL
,	NULL
peptides	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
before	NULL
use	NULL
as	NULL
target	NULL
cells	NULL
.	NULL

B	NULL
)	NULL
.	NULL

The	NULL
observed	NULL
lack	NULL
of	NULL
recognition	NULL
of	NULL
the	NULL
TAP1	NULL
'-	NULL
5E1-MECs	NULL
is	NULL
not	NULL
due	NULL
to	NULL
resistance	NULL
to	NULL
CTL-mediated	NULL
lysis	NULL
,	NULL
since	NULL
these	NULL
cells	NULL
were	NULL
lysed	NULL
when	NULL
pulsed	NULL
exogenously	NULL
with	NULL
synthetic	NULL
peptides	NULL
corresponding	NULL
to	NULL
the	NULL
E1A	NULL
and	NULL
E1B	NULL
CTL	NULL
epitopes	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

This	NULL
absence	NULL
of	NULL
recognition	NULL
is	NULL
also	NULL
not	NULL
due	NULL
to	NULL
the	NULL
sensitivity	NULL
differences	NULL
in	NULL
cloned	NULL
vs	NULL
short-term-cultured	NULL
CTLs	NULL
,	NULL
because	NULL
the	NULL
TAP1~'~	NULL
5E1-MECs	NULL
were	NULL
not	NULL
recognized	NULL
by	NULL
secondary	NULL
bulk	NULL
splenocytes	NULL
from	NULL
mice	NULL
immunized	NULL
with	NULL
5E1-MECs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
also	NULL
obtained	NULL
in	NULL
an	NULL
alternative	NULL
CTL	NULL
assay	NULL
in	NULL
which	NULL
the	NULL
secretion	NULL
of	NULL
TNF	NULL
by	NULL
CTLs	NULL
is	NULL
used	NULL
to	NULL
determine	NULL
CTL	NULL
recognition	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
TAP1	NULL
'~	NULL
5E1-MECs	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
wt	NULL
TAP	NULL
*'*	NULL
5E1-MEC	NULL
's	NULL
,	NULL
are	NULL
not	NULL
recognized	NULL
by	NULL
E1A-or	NULL
E1B-specific	NULL
CTLs	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
TAP	NULL
defect	NULL
in	NULL
the	NULL
TAP1	NULL
~~	NULL
5E1-MECs	NULL
prevents	NULL
class	NULL
I-restricted	NULL
presentation	NULL
of	NULL
the	NULL
endogenously	NULL
synthesized	NULL
E1A	NULL
and	NULL
E1B	NULL
epitopes	NULL
.	NULL

To	NULL
verify	NULL
that	NULL
lack	NULL
of	NULL
CTL	NULL
recognition	NULL
was	NULL
due	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
5E1-derived	NULL
peptides	NULL
in	NULL
the	NULL
ER	NULL
and	NULL
was	NULL
not	NULL
caused	NULL
by	NULL
defective	NULL
assembly	NULL
or	NULL
by	NULL
the	NULL
ER-to-surface	NULL
transport	NULL
of	NULL
peptide/MHC	NULL
complexes	NULL
,	NULL
a	NULL
signal	NULL
sequence-containing	NULL
minigene	NULL
was	NULL
used	NULL
to	NULL
target	NULL
E1A	NULL
or	NULL
E1B	NULL
epitope-containing	NULL
peptides	NULL
directly	NULL
to	NULL
the	NULL
ER	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Transfection	NULL
of	NULL
the	NULL
TAP1	NULL
~~	NULL
5E1-MECs	NULL
with	NULL
either	NULL
of	NULL
these	NULL
minigenes	NULL
resulted	NULL
in	NULL
their	NULL
recognition	NULL
by	NULL
the	NULL
relevant	NULL
CTLs	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
demonstrates	NULL
that	NULL
when	NULL
antigenic	NULL
peptides	NULL
are	NULL
provided	NULL
to	NULL
the	NULL
ER	NULL
,	NULL
E1A	NULL
and	NULL
E1B	NULL
epitope/MHC	NULL
complexes	NULL
are	NULL
properly	NULL
assembled	NULL
and	NULL
transported	NULL
to	NULL
the	NULL
cell	NULL
surface	NULL
for	NULL
recognition	NULL
by	NULL
CTLs	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
lack	NULL
of	NULL
TAP	NULL
function	NULL
in	NULL
the	NULL
TAP1	NULL
~~	NULL
5E1-MEC	NULL
's	NULL
results	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
5E1-derived	NULL
antigenic	NULL
peptides	NULL
in	NULL
the	NULL
ER	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

CUTTING	NULL
EDGE	NULL
100	NULL
]	NULL
a	NULL
100	NULL
]	NULL
B	NULL
75	NULL
75	NULL
50	NULL
50	NULL
25	NULL
25	NULL
./0—0\	NULL
.	NULL

.	NULL

o	NULL
--	NULL
-	NULL
»	NULL
D	NULL
2	NULL
07	NULL
r	NULL
o*	NULL
r	NULL
Ke	NULL
]	NULL
0	NULL
15	NULL
30	NULL
45	NULL
60	NULL
0	NULL
15	NULL
30	NULL
45	NULL
60	NULL
§	NULL
w	NULL
100	NULL
100	NULL
wo	NULL
C	NULL
D	NULL
0	NULL
75	NULL
75	NULL
25	NULL
D/D/D/G	NULL
25	NULL
M	NULL
Onge-~0~	NULL
map	NULL
07	NULL
0°	NULL
0	NULL
15	NULL
30	NULL
45	NULL
60	NULL
0	NULL
15	NULL
30	NULL
45	NULL
60	NULL
E/T	NULL
FIGURE	NULL
4	NULL
.	NULL

Immunization	NULL
with	NULL
TAP1*'*	NULL
5E1-MECs	NULL
and	NULL
TAP1	NULL
~	NULL
5E1-MECs	NULL
induces	NULL
El-specific	NULL
CTLs	NULL
.	NULL

C57BL/6	NULL
mice	NULL
were	NULL
immunized	NULL
s.c.	NULL
with	NULL
either	NULL
10	NULL
``	NULL
TAP*'*	NULL
5E1-MECs	NULL
(	NULL
4	NULL
and	NULL
C	NULL
)	NULL
or	NULL
TAP1	NULL
~~	NULL
5E1-MECs	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
in	NULL
0.2	NULL
ml	NULL
PBS	NULL
.	NULL

After	NULL
2	NULL
wk	NULL
,	NULL
splenocytes	NULL
were	NULL
restimulated	NULL
in	NULL
vitro	NULL
with	NULL
either	NULL
SigE1A	NULL
;	NULL
,	NULL
;	NULL
,	NULL
,	NULL
,	NULL
,	NULL
MECs	NULL
(	NULL
15	NULL
)	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
to	NULL
specifically	NULL
restimulate	NULL
the	NULL
quantitatively	NULL
weaker	NULL
E1A	NULL
CTL	NULL
response	NULL
(	NULL
18	NULL
)	NULL
or	NULL
with	NULL
TAP1	NULL
**	NULL
5E1-MECs	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
to	NULL
restimulate	NULL
E1B-specific	NULL
CTL	NULL
responses	NULL
.	NULL

After	NULL
a	NULL
6-day	NULL
coculture	NULL
,	NULL
the	NULL
lytic	NULL
activity	NULL
of	NULL
the	NULL
bulk	NULL
splenocytes	NULL
was	NULL
tested	NULL
against	NULL
the	NULL
following	NULL
target	NULL
cells	NULL
:	NULL
TAP1	NULL
***	NULL
5E1-MECs	NULL
(	NULL
C	NULL
)	NULL
)	NULL
or	NULL
TAP1	NULL
**	NULL
MECs	NULL
pulsed	NULL
with	NULL
either	NULL
E1A	NULL
;	NULL
,	NULL
;	NULL
,	NULL
,	NULL
,	NULL
,	NULL
peptide	NULL
(	NULL
0	NULL
)	NULL
or	NULL
3	NULL
,	NULL
peptide	NULL
(	NULL
@	NULL
)	NULL
.	NULL

The	NULL
percent	NULL
specific	NULL
lysis	NULL
at	NULL
various	NULL
E	NULL
:	NULL
T	NULL
ratios	NULL
is	NULL
depicted	NULL
.	NULL

Immunization	NULL
with	NULL
5EI-TAP1	NULL
~	NULL
MECs	NULL
induces	NULL
ElIA-	NULL
and	NULL
EIB-specific	NULL
CTL	NULL
responses	NULL
We	NULL
subsequently	NULL
investigated	NULL
whether	NULL
the	NULL
lack	NULL
of	NULL
El-derived	NULL
peptides	NULL
in	NULL
the	NULL
ER	NULL
of	NULL
immunizing	NULL
cells	NULL
would	NULL
affect	NULL
their	NULL
capacity	NULL
to	NULL
induce	NULL
E1A-	NULL
and	NULL
E1B-specific	NULL
CTL	NULL
responses	NULL
in	NULL
vivo	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
C57BL/6	NULL
mice	NULL
were	NULL
immunized	NULL
with	NULL
wt	NULL
TAP*'*	NULL
5E1-MECs	NULL
or	NULL
TAP1	NULL
~~	NULL
5E1-MEC	NULL
's	NULL
.	NULL

Bulk	NULL
splenocyte	NULL
cultures	NULL
from	NULL
mice	NULL
immunized	NULL
with	NULL
wt	NULL
TAP	NULL
``	NULL
'*	NULL
or	NULL
TAP1~'~	NULL
5E1-MECs	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
lyse	NULL
5E1-transformed	NULL
target	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
MECs	NULL
pulsed	NULL
with	NULL
the	NULL
E1A	NULL
and	NULL
E1B	NULL
peptides	NULL
.	NULL

Immunization	NULL
with	NULL
either	NULL
TAP	NULL
'~	NULL
or	NULL
TAP*'*	NULL
5E1-MECs	NULL
induces	NULL
a	NULL
strong	NULL
5El-specific	NULL
CTL	NULL
response	NULL
to	NULL
both	NULL
the	NULL
E1A	NULL
and	NULL
E1B	NULL
epitopes	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
cross-priming	NULL
of	NULL
MHC	NULL
class	NULL
I-restricted	NULL
CTL	NULL
responses	NULL
does	NULL
not	NULL
require	NULL
antigenic	NULL
peptides	NULL
in	NULL
the	NULL
ER	NULL
of	NULL
immunizing	NULL
cells	NULL
.	NULL

Discussion	NULL
Our	NULL
results	NULL
demonstrate	NULL
that	NULL
in	NULL
vivo	NULL
cross-priming	NULL
of	NULL
MHC	NULL
class	NULL
I-restricted	NULL
CTL	NULL
responses	NULL
against	NULL
cell-associated	NULL
Ags	NULL
does	NULL
not	NULL
require	NULL
TAP-transported	NULL
peptides	NULL
in	NULL
the	NULL
ER	NULL
of	NULL
immunizing	NULL
cells	NULL
.	NULL

Both	NULL
the	NULL
TAP*	NULL
``	NULL
*	NULL
and	NULL
TAP_'~	NULL
MECs	NULL
used	NULL
in	NULL
our	NULL
study	NULL
clearly	NULL
show	NULL
intracellular	NULL
expression	NULL
of	NULL
both	NULL
the	NULL
E1A	NULL
and	NULL
E1B	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
;	NULL
however	NULL
,	NULL
only	NULL
the	NULL
TAP*'*	NULL
5E1-MECs	NULL
were	NULL
recognized	NULL
by	NULL
E1	NULL
A-	NULL
or	NULL
E1B-specific	NULL
CTLs	NULL
.	NULL

CTL	NULL
recognition	NULL
of	NULL
the	NULL
TAP1	NULL
'~	NULL
5E1-MECs	NULL
could	NULL
be	NULL
restored	NULL
by	NULL
exogenous	NULL
addition	NULL
of	NULL
synthetic	NULL
peptides	NULL
comprising	NULL
the	NULL
E1A	NULL
and	NULL
E1B	NULL
epitopes	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

As	NULL
CTL	NULL
triggering	NULL
is	NULL
thought	NULL
to	NULL
require	NULL
very	NULL
few	NULL
peptide/MHC	NULL
complexes	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
CTL	NULL
recognition	NULL
indicates	NULL
the	NULL
absence	NULL
of	NULL
surface	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
containing	NULL
E1A-	NULL
and	NULL
E1B-derived	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
antigenic	NULL
peptides	NULL
(	NULL
22	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
the	NULL
TAP1~'~	NULL
5E1-MECs	NULL
are	NULL
recognized	NULL
by	NULL
CTLs	NULL
when	NULL
longer	NULL
peptides	NULL
containing	NULL
the	NULL
E1A	NULL
or	NULL
E1B	NULL
epitopes	NULL
were	NULL
provided	NULL
directly	NULL
to	NULL
the	NULL
ER	NULL
in	NULL
a	NULL
TAP-independent	NULL
fashion	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
C	NULL
and	NULL
1D	NULL
)	NULL
confirms	NULL
that	NULL
the	NULL
recognition	NULL
defect	NULL
lies	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
5E1-derived	NULL
antigenic	NULL
peptides	NULL
in	NULL
the	NULL
ER	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
TAP1~'~	NULL
5E1-MEC	NULL
's	NULL
are	NULL
able	NULL
to	NULL
efficiently	NULL
cross-prime	NULL
E1A-	NULL
and	NULL
E1B-specific	NULL
CTL	NULL
responses	NULL
in	NULL
vivo	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
mechanism	NULL
of	NULL
cross-priming	NULL
does	NULL
not	NULL
depend	NULL
upon	NULL
the	NULL
presence	NULL
of	NULL
peptides	NULL
in	NULL
the	NULL
ER	NULL
of	NULL
immunizing	NULL
cells	NULL
as	NULL
a	NULL
source	NULL
of	NULL
Ag	NULL
for	NULL
transfer	NULL
to	NULL
host	NULL
APCs	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
relevant	NULL
for	NULL
understanding	NULL
the	NULL
physiologic	NULL
role	NULL
of	NULL
peptide-binding	NULL
ER	NULL
proteins	NULL
such	NULL
as	NULL
gp96	NULL
in	NULL
cross-priming	NULL
.	NULL

As	NULL
mentioned	NULL
previously	NULL
,	NULL
a	NULL
cross-priming	NULL
pathway	NULL
that	NULL
operates	NULL
via	NULL
the	NULL
transfer	NULL
of	NULL
ER	NULL
peptides	NULL
from	NULL
immunizing	NULL
cells	NULL
to	NULL
host	NULL
APCs	NULL
would	NULL
simplify	NULL
the	NULL
``	NULL
choices	NULL
``	NULL
faced	NULL
by	NULL
APCs	NULL
concerning	NULL
whether	NULL
a	NULL
given	NULL
phagocytosed	NULL
Ag	NULL
should	NULL
be	NULL
shunted	NULL
to	NULL
the	NULL
MHC	NULL
class	NULL
I	NULL
vs	NULL
class	NULL
II	NULL
pathways	NULL
.	NULL

It	NULL
would	NULL
be	NULL
of	NULL
no	NULL
obvious	NULL
advantage	NULL
for	NULL
the	NULL
APCs	NULL
to	NULL
present	NULL
all	NULL
phagocytosed	NULL
material	NULL
via	NULL
class	NULL
I	NULL
,	NULL
as	NULL
only	NULL
a	NULL
subset	NULL
of	NULL
these	NULL
antigenic	NULL
complexes	NULL
would	NULL
be	NULL
likely	NULL
to	NULL
be	NULL
encountered	NULL
on	NULL
target	NULL
cells	NULL
in	NULL
the	NULL
periphery	NULL
.	NULL

A	NULL
gp96-dependent	NULL
cross-priming	NULL
pathway	NULL
would	NULL
solve	NULL
this	NULL
problem	NULL
by	NULL
focusing	NULL
CTL	NULL
responses	NULL
to	NULL
antigenic	NULL
peptides	NULL
that	NULL
are	NULL
destined	NULL
for	NULL
loading	NULL
onto	NULL
class	NULL
I	NULL
molecules	NULL
of	NULL
target	NULL
cells	NULL
.	NULL

Although	NULL
purified	NULL
gp96	NULL
prepara-tions	NULL
,	NULL
like	NULL
many	NULL
cell-derived	NULL
immunogens	NULL
,	NULL
can	NULL
clearly	NULL
be	NULL
used	NULL
to	NULL
immunize	NULL
for	NULL
specific	NULL
CTL	NULL
responses	NULL
,	NULL
our	NULL
data	NULL
show	NULL
that	NULL
gp96	NULL
does	NULL
not	NULL
represent	NULL
an	NULL
essential	NULL
component	NULL
of	NULL
the	NULL
in	NULL
vivo	NULL
cross-priming	NULL
pathway	NULL
for	NULL
cell-associated	NULL
Ag	NULL
.	NULL

The	NULL
immunogenicity	NULL
of	NULL
gp96	NULL
preparations	NULL
was	NULL
first	NULL
revealed	NULL
by	NULL
experiments	NULL
which	NULL
used	NULL
cell	NULL
fractionation	NULL
to	NULL
identify	NULL
Ag	NULL
(	NULL
s	NULL
)	NULL
underlying	NULL
the	NULL
ability	NULL
of	NULL
tumor-cell	NULL
vaccination	NULL
to	NULL
confer	NULL
protective	NULL
immunity	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Following	NULL
the	NULL
challenge	NULL
of	NULL
mice	NULL
immunized	NULL
with	NULL
specific	NULL
cellular	NULL
fractions	NULL
,	NULL
it	NULL
was	NULL
found	NULL
that	NULL
the	NULL
tumor-derived	NULL
gp96	NULL
(	NULL
bound	NULL
to	NULL
tumor	NULL
peptides	NULL
)	NULL
alone	NULL
could	NULL
confer	NULL
protective	NULL
immunity	NULL
.	NULL

This	NULL
observation	NULL
led	NULL
to	NULL
the	NULL
notion	NULL
that	NULL
the	NULL
gp96/peptide	NULL
complexes	NULL
mediated	NULL
the	NULL
immunogenicity	NULL
of	NULL
the	NULL
tumor	NULL
cells	NULL
(	NULL
5	NULL
,	NULL
23	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
possibility	NULL
exists	NULL
that	NULL
the	NULL
experimental	NULL
approach	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
may	NULL
have	NULL
biased	NULL
the	NULL
outcome	NULL
of	NULL
the	NULL
immunizations	NULL
.	NULL

Whereas	NULL
certain	NULL
synthetic	NULL
peptides	NULL
are	NULL
able	NULL
to	NULL
prime	NULL
CTLs	NULL
without	NULL
adjuvants	NULL
,	NULL
injection	NULL
of	NULL
soluble	NULL
protein	NULL
does	NULL
not	NULL
generally	NULL
induce	NULL
CTL	NULL
responses	NULL
(	NULL
24	NULL
)	NULL
.	NULL

When	NULL
offered	NULL
as	NULL
an	NULL
exogenous	NULL
Ag	NULL
without	NULL
adjuvants	NULL
,	NULL
the	NULL
only	NULL
tumor-derived	NULL
cellular	NULL
fraction	NULL
able	NULL
to	NULL
induce	NULL
class	NULL
I-restricted	NULL
tumor-specific	NULL
CTLs	NULL
would	NULL
likely	NULL
have	NULL
to	NULL
be	NULL
either	NULL
a	NULL
peptide	NULL
or	NULL
a	NULL
peptide	NULL
chaperone	NULL
such	NULL
as	NULL
gp96	NULL
.	NULL

This	NULL
view	NULL
suggests	NULL
that	NULL
the	NULL
mechanism	NULL
for	NULL
induction	NULL
of	NULL
protective	NULL
immunity	NULL
by	NULL
tumor	NULL
cell	NULL
vaccination	NULL
may	NULL
not	NULL
be	NULL
the	NULL
same	NULL
as	NULL
that	NULL
elicited	NULL
by	NULL
immunization	NULL
with	NULL
purified	NULL
gp96	NULL
.	NULL

Our	NULL
present	NULL
results	NULL
support	NULL
and	NULL
extend	NULL
this	NULL
idea	NULL
by	NULL
showing	NULL
that	NULL
tumor	NULL
cells	NULL
in	NULL
which	NULL
antigenic	NULL
peptides	NULL
do	NULL
not	NULL
reach	NULL
the	NULL
ER	NULL
,	NULL
and	NULL
therefore	NULL
can	NULL
not	NULL
endogenously	NULL
associate	NULL
with	NULL
gp96	NULL
,	NULL
are	NULL
nevertheless	NULL
able	NULL
to	NULL
efficiently	NULL
cross-prime	NULL
CTL	NULL
responses	NULL
.	NULL

Although	NULL
we	NULL
can	NULL
not	NULL
formally	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
El-derived	NULL
antigenic	NULL
peptides	NULL
were	NULL
able	NULL
to	NULL
associate	NULL
with	NULL
gp96	NULL
in	NULL
the	NULL
cytoplasm	NULL
or	NULL
extracellular	NULL
environment	NULL
when	NULL
released	NULL
from	NULL
the	NULL
dying	NULL
TAP	NULL
'~	NULL
cells	NULL
,	NULL
this	NULL
option	NULL
is	NULL
considered	NULL
unlikely	NULL
in	NULL
light	NULL
of	NULL
the	NULL
recent	NULL
report	NULL
indicating	NULL
that	NULL
gp96	NULL
isolated	NULL
from	NULL
TAP-defective	NULL
cells	NULL
did	NULL
not	NULL
associate	NULL
with	NULL
antigenic	NULL
peptides	NULL
following	NULL
lysis	NULL
of	NULL
these	NULL
cells	NULL
in	NULL
vitro	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
results	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
peptide-binding	NULL
ER	NULL
proteins	NULL
such	NULL
as	NULL
gp96	NULL
or	NULL
those	NULL
described	NULL
recently	NULL
by	NULL
others	NULL
do	NULL
not	NULL
comprise	NULL
essential	NULL
components	NULL
of	NULL
the	NULL
Ag-transfer	NULL
mechanism	NULL
operative	NULL
in	NULL
in	NULL
vivo	NULL
cross-priming	NULL
(	NULL
9	NULL
,	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
mode	NULL
of	NULL
transfer	NULL
of	NULL
antigenic	NULL
material	NULL
from	NULL
immunizing	NULL
cells	NULL
to	NULL
host	NULL
APCs	NULL
during	NULL
cross-priming	NULL
remains	NULL
a	NULL
compelling	NULL
3811	NULL
question	NULL
with	NULL
important	NULL
implications	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
CTL	NULL
responses	NULL
through	NULL
specific	NULL
vaccination	NULL
.	NULL

As	NULL
noted	NULL
by	NULL
Bevan	NULL
,	NULL
particulate	NULL
Ag	NULL
in	NULL
the	NULL
form	NULL
of	NULL
damaged	NULL
cells	NULL
would	NULL
effectively	NULL
limit	NULL
the	NULL
wide	NULL
range	NULL
of	NULL
endocytosed	NULL
Ags	NULL
to	NULL
those	NULL
best	NULL
shunted	NULL
to	NULL
the	NULL
class	NULL
I	NULL
pathway	NULL
for	NULL
presentation	NULL
to	NULL
CTLs	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Recent	NULL
evidence	NULL
for	NULL
the	NULL
shedding	NULL
of	NULL
antigenic	NULL
vesicles	NULL
,	NULL
the	NULL
release	NULL
of	NULL
apoptotic	NULL
blebs	NULL
from	NULL
cells	NULL
,	NULL
or	NULL
their	NULL
apparent	NULL
transfer	NULL
to	NULL
dendritic	NULL
cells	NULL
in	NULL
vitro	NULL
raises	NULL
interesting	NULL
possibilities	NULL
with	NULL
regard	NULL
to	NULL
how	NULL
cell-associated	NULL
Ags	NULL
are	NULL
obtained	NULL
by	NULL
APCs	NULL
(	NULL
28-30	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
do	NULL
not	NULL
argue	NULL
against	NULL
the	NULL
possibility	NULL
that	NULL
other	NULL
hsps	NULL
,	NULL
such	NULL
as	NULL
hsp70	NULL
,	NULL
may	NULL
play	NULL
a	NULL
direct	NULL
role	NULL
in	NULL
Ag	NULL
transfer	NULL
to	NULL
APCs	NULL
.	NULL

A	NULL
clearer	NULL
understanding	NULL
of	NULL
the	NULL
mechanism	NULL
underlying	NULL
cross-presentation	NULL
of	NULL
Ags	NULL
to	NULL
CTLs	NULL
is	NULL
an	NULL
important	NULL
goal	NULL
toward	NULL
the	NULL
development	NULL
of	NULL
more	NULL
effective	NULL
methods	NULL
of	NULL
inducing	NULL
immunity	NULL
against	NULL
tumors	NULL
and	NULL
infectious	NULL
agents	NULL
as	NULL
well	NULL
as	NULL
controlling	NULL
the	NULL
pathologic	NULL
effects	NULL
of	NULL
autoimmunity	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Dr.	NULL
Frits	NULL
Koning	NULL
for	NULL
critical	NULL
evaluation	NULL
of	NULL
the	NULL
manuscript	NULL
and	NULL
Dr.	NULL
Stephen	NULL
S.	NULL
Wilson	NULL
and	NULL
Jan	NULL
Beentjes	NULL
for	NULL
assistance	NULL
in	NULL
preparing	NULL
the	NULL
pho-tomicrographs	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Bevan	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

1976	NULL
.	NULL

Cross-priming	NULL
for	NULL
a	NULL
secondary	NULL
cytotoxic	NULL
response	NULL
to	NULL
minor	NULL
H	NULL
antigens	NULL
with	NULL
H-2	NULL
congenic	NULL
cells	NULL
which	NULL
do	NULL
not	NULL
cross-react	NULL
in	NULL
the	NULL
cytotoxic	NULL
assay	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

143:1283	NULL
.	NULL

2	NULL
.	NULL

Bevan	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

1995	NULL
.	NULL

Antigen	NULL
presentation	NULL
to	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:639	NULL
.	NULL

3	NULL
.	NULL

Heath	NULL
,	NULL
W.	NULL
R.	NULL
,	NULL
C.	NULL
Kurts	NULL
,	NULL
J.	NULL
Miller	NULL
,	NULL
and	NULL
F.	NULL
R.	NULL
Carbone	NULL
.	NULL

1998	NULL
.	NULL

Cross-tolerance	NULL
:	NULL
a	NULL
pathway	NULL
for	NULL
inducing	NULL
tolerance	NULL
to	NULL
peripheral	NULL
tissue	NULL
antigens	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187	NULL
;	NULL
1549	NULL
.	NULL

4	NULL
.	NULL

Huang	NULL
,	NULL
A.	NULL
Y.	NULL
,	NULL
P.	NULL
Golumbeck	NULL
,	NULL
M.	NULL
Ahmadzadeh	NULL
,	NULL
E.	NULL
Jaffe	NULL
,	NULL
D.	NULL
M.	NULL
Pardoll	NULL
,	NULL
and	NULL
H.	NULL
I.	NULL
Levitsky	NULL
.	NULL

1994	NULL
.	NULL

Role	NULL
of	NULL
bone	NULL
marrow-derived	NULL
cells	NULL
in	NULL
presenting	NULL
MHC	NULL
class	NULL
T-restricted	NULL
tumor	NULL
antigens	NULL
.	NULL

Science	NULL
264:961	NULL
.	NULL

5	NULL
.	NULL

Srivastava	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
DeLeo	NULL
,	NULL
and	NULL
L.	NULL
J	NULL
.	NULL

Old	NULL
.	NULL

1986	NULL
.	NULL

Tumor	NULL
rejection	NULL
antigens	NULL
of	NULL
chemically	NULL
induced	NULL
sarcomas	NULL
of	NULL
inbred	NULL
mice	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83	NULL
:	NULL
3407	NULL
.	NULL

6	NULL
.	NULL

Ullrich	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
E.	NULL
A.	NULL
Robinson	NULL
,	NULL
L.	NULL
W.	NULL
Law	NULL
,	NULL
M.	NULL
Willingham	NULL
,	NULL
and	NULL
E.	NULL
Appella	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
mouse	NULL
tumor-specific	NULL
transplantation	NULL
antigen	NULL
is	NULL
a	NULL
heat-shock	NULL
related	NULL
protein	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:3077	NULL
.	NULL

7	NULL
.	NULL

Blachere	NULL
,	NULL
N.	NULL
E.	NULL
,	NULL
Z.	NULL
Li	NULL
,	NULL
R.	NULL
Y.	NULL
Chandawarkar	NULL
,	NULL
R.	NULL
Suto	NULL
,	NULL
N.	NULL
S.	NULL
Jaikaria	NULL
,	NULL
S.	NULL
Basu	NULL
,	NULL
H.	NULL
Udono	NULL
,	NULL
and	NULL
P.	NULL
K.	NULL
Srivastava	NULL
.	NULL

1997	NULL
.	NULL

Heat	NULL
shock	NULL
protein-peptide	NULL
complexes	NULL
,	NULL
reconstituted	NULL
in	NULL
vitro	NULL
,	NULL
elicit	NULL
peptide-specific	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
response	NULL
and	NULL
tumor	NULL
immunity	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:1315	NULL
.	NULL

8	NULL
.	NULL

Lindquist	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
E.	NULL
A.	NULL
Craig	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
heat	NULL
shock	NULL
proteins	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Genet	NULL
.	NULL

22:631	NULL
.	NULL

9	NULL
.	NULL

Lammert	NULL
,	NULL
E.	NULL
,	NULL
D.	NULL
Arnold	NULL
,	NULL
M.	NULL
Nijenhuis	NULL
,	NULL
F.	NULL
Momburg	NULL
,	NULL
G.	NULL
J.	NULL
Hammerling	NULL
,	NULL
J.	NULL
Brunner	NULL
,	NULL
S.	NULL
Stevanovic	NULL
,	NULL
H.	NULL
G.	NULL
Rammensee	NULL
,	NULL
and	NULL
H.	NULL
Schild	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
endoplasmic	NULL
reticulum-resident	NULL
stress	NULL
protein	NULL
gp96	NULL
binds	NULL
peptides	NULL
translocated	NULL
by	NULL
TAP	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27:923	NULL
.	NULL

10	NULL
.	NULL

Srivastava	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
H.	NULL
Udono	NULL
,	NULL
N.	NULL
E.	NULL
Blachere	NULL
,	NULL
and	NULL
Z.	NULL
Li	NULL
.	NULL

1994	NULL
.	NULL

Heat	NULL
shock	NULL
proteins	NULL
transfer	NULL
peptides	NULL
during	NULL
antigen	NULL
processing	NULL
and	NULL
CTL	NULL
priming	NULL
.	NULL

Immunogenetics	NULL
39:93	NULL
.	NULL

11	NULL
.	NULL

Udono	NULL
,	NULL
H.	NULL
,	NULL
D.	NULL
L.	NULL
Levey	NULL
,	NULL
and	NULL
P.	NULL
K.	NULL
Srivastava	NULL
.	NULL

1994	NULL
.	NULL

Cellular	NULL
requirements	NULL
for	NULL
tumor-specific	NULL
immunity	NULL
elicited	NULL
by	NULL
heat	NULL
shock	NULL
proteins	NULL
:	NULL
tumor	NULL
rejection	NULL
antigen	NULL
gp96	NULL
primes	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:3077	NULL
.	NULL

12	NULL
.	NULL

Arnold	NULL
,	NULL
D.	NULL
,	NULL
S.	NULL
Faath	NULL
,	NULL
and	NULL
H.	NULL
Rammensee	NULL
.	NULL

1995	NULL
.	NULL

Cross-priming	NULL
of	NULL
minor	NULL
histo-compatibility	NULL
antigen-specific	NULL
cytotoxic	NULL
T	NULL
cells	NULL
upon	NULL
immunization	NULL
with	NULL
heat	NULL
shock	NULL
protein	NULL
gp96	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:885	NULL
.	NULL

13	NULL
.	NULL

Nieland	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
M.	NULL
C.	NULL
Tan	NULL
,	NULL
M.	NULL
Monne-van	NULL
Muijen	NULL
,	NULL
F.	NULL
Koning	NULL
,	NULL
A.	NULL
M.	NULL
Kruisbeck	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
van	NULL
Bleek	NULL
.	NULL

1996	NULL
.	NULL

Isolation	NULL
of	NULL
an	NULL
immunodominant	NULL
viral	NULL
peptide	NULL
that	NULL
is	NULL
endogenously	NULL
bound	NULL
to	NULL
the	NULL
stress	NULL
protein	NULL
gp96/GRP94	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:6135	NULL
.	NULL

14	NULL
.	NULL

Suto	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
P.	NULL
K.	NULL
Srivastava	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
mechanism	NULL
for	NULL
the	NULL
specific	NULL
immunogenicity	NULL
of	NULL
heat	NULL
shock	NULL
protein-chaperoned	NULL
peptides	NULL
.	NULL

Science	NULL
269:1585	NULL
.	NULL

15	NULL
.	NULL

Kast	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
R.	NULL
Offringa	NULL
,	NULL
P.	NULL
J.	NULL
Peters	NULL
,	NULL
A.	NULL
C.	NULL
Voordouw	NULL
,	NULL
R.	NULL
H.	NULL
Meloen	NULL
,	NULL
A.	NULL
J.	NULL
van	NULL
der	NULL
Eb	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
.	NULL

1989	NULL
.	NULL

Eradication	NULL
of	NULL
adenovirus	NULL
E1	NULL
-induced	NULL
tumors	NULL
by	NULL
Ela-specific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
59:603	NULL
.	NULL

16	NULL
.	NULL

Schoenberger	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
L.	NULL
E.	NULL
Jonges	NULL
,	NULL
R.	NULL
J.	NULL
D.	NULL
Mooijaart	NULL
,	NULL
F.	NULL
Hartgers	NULL
,	NULL
R.	NULL
E.	NULL
M.	NULL
Toes	NULL
,	NULL
W.	NULL
M.	NULL
Kast	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
,	NULL
and	NULL
R.	NULL
Offringa	NULL
.	NULL

1998	NULL
.	NULL

Efficient	NULL
direct	NULL
priming	NULL
of	NULL
tumor-specific	NULL
CTL	NULL
in	NULL
vivo	NULL
by	NULL
an	NULL
engineered	NULL
APC	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

58:3094	NULL
.	NULL

17	NULL
.	NULL

Harlow	NULL
,	NULL
E.	NULL
,	NULL
B.	NULL
R.	NULL
Franza	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
C.	NULL
Schley	NULL
.	NULL

1985	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
specific	NULL
for	NULL
adenovirus	NULL
early	NULL
region	NULL
1A	NULL
proteins	NULL
:	NULL
extensive	NULL
heterogeneity	NULL
in	NULL
carly	NULL
region	NULL
1A	NULL
products	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

55:533	NULL
.	NULL

18.	NULL
van	NULL
den	NULL
Heuvel	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
T.	NULL
van	NULL
Laar	NULL
,	NULL
W.	NULL
M.	NULL
Kast	NULL
,	NULL
C.	NULL
J.	NULL
Melief	NULL
,	NULL
A.	NULL
Zantema	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
van	NULL
der	NULL
Eb	NULL
.	NULL

1990	NULL
.	NULL

Association	NULL
between	NULL
the	NULL
cellular	NULL
p53	NULL
and	NULL
the	NULL
adenovirus	NULL
5	NULL
E1B-55kd	NULL
proteins	NULL
reduces	NULL
the	NULL
oncogenicity	NULL
of	NULL
Ad-transformed	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

19:2621	NULL
.	NULL

19	NULL
.	NULL

Toes	NULL
,	NULL
R.	NULL
E.	NULL
M.	NULL
,	NULL
R.	NULL
Offringa	NULL
,	NULL
R.	NULL
J.	NULL
J.	NULL
Blom	NULL
,	NULL
R.	NULL
M.	NULL
P.	NULL
Brandt	NULL
,	NULL
A.	NULL
J.	NULL
van	NULL
der	NULL
Eb	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
,	NULL
and	NULL
W.	NULL
M.	NULL
Kast	NULL
.	NULL

1995	NULL
.	NULL

An	NULL
adenovirus	NULL
type	NULL
5	NULL
early	NULL
region	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
3812	NULL
20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

1B-encoded	NULL
CTL-mediating	NULL
tumor	NULL
eradication	NULL
by	NULL
CTL	NULL
clones	NULL
is	NULL
down-modulated	NULL
by	NULL
an	NULL
activated	NULL
ras	NULL
oncogene	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:3396	NULL
.	NULL

Traversari	NULL
,	NULL
C.	NULL
,	NULL
P.	NULL
van	NULL
der	NULL
Bruggen	NULL
,	NULL
B.	NULL
van	NULL
den	NULL
Eynde	NULL
,	NULL
P.	NULL
Hainaut	NULL
,	NULL
C.	NULL
Lemoine	NULL
,	NULL
N.	NULL
Ohta	NULL
,	NULL
L.	NULL
Old	NULL
,	NULL
and	NULL
T.	NULL
Boon	NULL
.	NULL

1992	NULL
.	NULL

Transfection	NULL
and	NULL
expression	NULL
of	NULL
a	NULL
gene	NULL
coding	NULL
for	NULL
a	NULL
human	NULL
melanoma	NULL
antigen	NULL
recognized	NULL
by	NULL
autologous	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Immunogenetics	NULL
35:145	NULL
.	NULL

Anderson	NULL
,	NULL
K.	NULL
,	NULL
P.	NULL
Cresswell	NULL
,	NULL
M.	NULL
Gammon	NULL
,	NULL
J.	NULL
Hermes	NULL
,	NULL
A.	NULL
Williamson	NULL
,	NULL
and	NULL
H.	NULL
Zweerink	NULL
.	NULL

1991	NULL
.	NULL

Endogenously	NULL
synthesized	NULL
peptide	NULL
with	NULL
an	NULL
endoplasmic	NULL
reticulum	NULL
signal	NULL
sequence	NULL
sensitizes	NULL
antigen-processing	NULL
mutant	NULL
cells	NULL
to	NULL
class	NULL
T-restricted	NULL
cell-mediated	NULL
lysis	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

174:489	NULL
.	NULL

Sykulev	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Joo	NULL
,	NULL
I.	NULL
Vturina	NULL
,	NULL
T.	NULL
J.	NULL
Tsomides	NULL
,	NULL
and	NULL
H.	NULL
J.	NULL
Eisen	NULL
.	NULL

1996	NULL
.	NULL

Evidence	NULL
that	NULL
a	NULL
single	NULL
peptide-MHC	NULL
complex	NULL
on	NULL
a	NULL
target	NULL
cell	NULL
can	NULL
elicit	NULL
a	NULL
cytolytic	NULL
T	NULL
cell	NULL
response	NULL
.	NULL

Immunity	NULL
4:565	NULL
.	NULL

Palladino	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Jr.	NULL
,	NULL
P.	NULL
K.	NULL
Srivastava	NULL
,	NULL
H.	NULL
F.	NULL
Octigen	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Delco	NULL
.	NULL

1987	NULL
.	NULL

Expression	NULL
of	NULL
a	NULL
shared	NULL
tumor-specific	NULL
antigen	NULL
by	NULL
two	NULL
chemically	NULL
induced	NULL
BALB/c	NULL
sarcomas	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

47:5074	NULL
.	NULL

Jondal	NULL
,	NULL
M.	NULL
,	NULL
R.	NULL
Schirmbeck	NULL
,	NULL
and	NULL
J.	NULL
Reimann	NULL
.	NULL

1996	NULL
.	NULL

MHC	NULL
class	NULL
T-restricted	NULL
CTL	NULL
responses	NULL
to	NULL
exogenous	NULL
antigens	NULL
.	NULL

Immunity	NULL
5:295	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

CUTTING	NULL
EDGE	NULL
Marusina	NULL
,	NULL
K.	NULL
,	NULL
G.	NULL
Reid	NULL
,	NULL
R.	NULL
Gabathuler	NULL
,	NULL
W.	NULL
Jeffries	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Monaco	NULL
.	NULL

1997	NULL
.	NULL

Novel	NULL
peptide	NULL
binding	NULL
proteins	NULL
and	NULL
peptide	NULL
transport	NULL
in	NULL
normal	NULL
and	NULL
TAP-deficient	NULL
mi-crosomes	NULL
.	NULL

Biochemistry	NULL
36:856	NULL
.	NULL

Spee	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
J.	NULL
Neefjes	NULL
.	NULL

1997	NULL
.	NULL

TAP-translocated	NULL
peptides	NULL
specifically	NULL
bind	NULL
proteins	NULL
in	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
,	NULL
including	NULL
gp96	NULL
,	NULL
protein	NULL
disulfide	NULL
isomerase	NULL
,	NULL
and	NULL
calreticulin	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27:2441	NULL
.	NULL

Bevan	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

1987	NULL
.	NULL

Class	NULL
discrimination	NULL
in	NULL
the	NULL
world	NULL
of	NULL
immunology	NULL
.	NULL

Nature	NULL
325:192	NULL
.	NULL

Raposo	NULL
,	NULL
G.	NULL
,	NULL
H.	NULL
W.	NULL
Nijman	NULL
,	NULL
W.	NULL
Stoorvogel	NULL
,	NULL
R.	NULL
Leijendekker	NULL
,	NULL
C.	NULL
V.	NULL
Harding	NULL
,	NULL
C.	NULL
J.	NULL
Melief	NULL
,	NULL
and	NULL
H.	NULL
J.	NULL
Geuze	NULL
.	NULL

1996	NULL
.	NULL

B	NULL
lymphocytes	NULL
secrete	NULL
antigen-presenting	NULL
vesicles	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183	NULL
:	NULL
1161	NULL
.	NULL

Casciola-Rosen	NULL
,	NULL
L.	NULL
,	NULL
A.	NULL
Rosen	NULL
,	NULL
M.	NULL
Petri	NULL
,	NULL
and	NULL
M.	NULL
Schlissel	NULL
.	NULL

1996	NULL
.	NULL

Surface	NULL
blebs	NULL
on	NULL
apoptotic	NULL
cells	NULL
are	NULL
sites	NULL
of	NULL
enhanced	NULL
procoagulant	NULL
activity	NULL
:	NULL
implications	NULL
for	NULL
coagulation	NULL
events	NULL
and	NULL
antigenic	NULL
spread	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:1624	NULL
.	NULL

Albert	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
B.	NULL
Sauter	NULL
,	NULL
and	NULL
N.	NULL
Bhardwaj	NULL
.	NULL

1998	NULL
.	NULL

Dendritic	NULL
cells	NULL
acquire	NULL
antigen	NULL
from	NULL
apoptotic	NULL
cells	NULL
and	NULL
induce	NULL
class	NULL
L-restricted	NULL
CTLs	NULL
.	NULL

Nature	NULL
392:86	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL

